Surgical outcomes after breast cancer surgery: measuring acute lymphedema.

BACKGROUND Studies of lymphedema have used inconsistent measures and criteria. The purpose of this pilot study was to measure the onset and incidence of acute lymphedema in breast cancer survivors using strict criteria for limb evaluation. MATERIALS AND METHODS Eligible women were those undergoing breast cancer surgery that included axillary staging and/or radiation therapy of the breast. Arm volume, strength, and flexibility were measured preoperatively and quarterly. Lymphedema was defined as a greater than 10% increase in limb volume. Additional strength and flexibility assessments were done at these times. RESULTS In 30 evaluable patients, half underwent modified radical mastectomy and half lumpectomy, with half of the lumpectomy patients undergoing axillary node staging. Of the 30 patients 27% were Stage 0; the rest were Stage I (27%), IIA (13%), IIB (23%), and IIIA (7%). One subject was IIIB postoperatively. There were 2 women with a 10% or greater change in limb volume; the change was detected in one woman at 3 months (5% incidence) and in the second woman at 6 months (11% incidence). Both had undergone mastectomy and axillary dissection and one of these two women had symptoms of tingling and numbness in the affected arm that began at 3 months. Overall, 35% of the sample experienced symptoms by 3 months, which included numbness, aching, and tingling of the entire upper extremity, but without volume changes. The relationship between undergoing modified radical mastectomy and experiencing symptoms in the affected limb at 3 months was significant (P = 0.05). CONCLUSIONS In this interim report strict methods of measurement and limb volume comparisons detected acute lymphedema at 3 months in 5% of the sample, and at 6 months in 11% of the sample. Furthermore, symptoms were detected in 35% without volume changes at 3 months postoperatively, which may warn of lymphedema occurrence within the next 3 months. This may assist clinical evaluation of symptoms in the postoperative period and support early referral to lymphedema experts.

[1]  J. Vaidya,et al.  Diseases of the breast , 2000, British Journal of Cancer.

[2]  D. Roses,et al.  Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. , 1999, Annals of surgery.

[3]  L. Gerber,et al.  A review of measures of lymphedema , 1998, Cancer.

[4]  M. Brennan,et al.  Workgroup III , 1998 .

[5]  J. Petrek,et al.  Incidence of breast carcinoma‐related lymphedema , 1998, Cancer.

[6]  P. Pressman,et al.  Surgical treatment and lymphedema , 1998, Cancer.

[7]  A. Meek Breast radiotherapy and lymphedema , 1998, Cancer.

[8]  S. Passik,et al.  Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma , 1998, Cancer.

[9]  P. Ridings,et al.  Modern trends in breast cancer therapy: towards less lymphoedema? , 1998, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  A. Szuba,et al.  Lymphedema: Anatomy, Physiology and Pathogenesis , 1997, Vascular medicine.

[11]  M. P. Moore,et al.  Axillary lymphadenectomy: A diagnostic and therapeutic procedure , 1997, Journal of surgical oncology.

[12]  A. Giuliano,et al.  Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. , 1997, Annals of surgery.

[13]  Umberto Veronesi,et al.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes , 1997, The Lancet.

[14]  Carter Bj Women's experiences of lymphedema. , 1997 .

[15]  D S Tulsky,et al.  Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. R. del Turco,et al.  Long-Term Sequelae of Breast Cancer Surgery , 1996, Tumori.

[17]  R. Depompolo,et al.  Focused review: postmastectomy lymphedema. , 1996, Archives of physical medicine and rehabilitation.

[18]  R. Steele,et al.  The Edinburgh randomized trial of axillary sampling or clearance after mastectomy , 1995, The British journal of surgery.

[19]  L. Gillham Modern Treatment for Lymphoedema , 1995 .

[20]  J. Sitzia Volume measurement in lymphoedema treatment: examination of formulae. , 1995, European journal of cancer care.

[21]  P. Mortimer,et al.  The psychological morbidity of breast cancer–related arm swelling. Psychological morbidity of lymphoedema , 1993, Cancer.

[22]  B. J. Carter Long‐term survivors of breast cancer: A qualitative descriptive study , 1993, Cancer nursing.

[23]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Royle,et al.  Assessment of morbidity from complete axillary dissection. , 1992, British Journal of Cancer.

[25]  S. Huchcroft,et al.  Arm function after axillary dissection for breast cancer: A pilot study to provide parameter estimates , 1992, Journal of surgical oncology.

[26]  R. Aitken,et al.  Arm morbidity within a trial of mastectomy and either nodal sample with selective radiotherapy or axillary clearance , 1989, The British journal of surgery.

[27]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[28]  M. Brennan,et al.  Diagnosis and Management of Lymphedema , 1998 .